1 The N-acetylation of dapsone (DDS) was studied in 108 unrelated Chinese subjects residing in the mainland of China. 2 The frequency of slow acetylators determined using the plasma monoacetyldapsone to DDS ratio (MADDS/DDS, slow acetylators < 0.30 and rapid acetylators > 0.35) at 3 h after an oral dose of DDS (100 mg) was 13.0% (14 of the 108 subjects) with a 95% confidence interval of 7.9 to 20.6%. 3 The mean plasma concentration of MADDS was about three times lower in the slow than in the rapid acetylators and there was a highly significant correlation (r, = 0.886, P < 0.001) between plasma MADDS concentration and acetylation ratio. 4 Urinary acetylation ratios (MADDS/DDS) and cumulative urinary excretion of MADDS were significantly (P < 0.001) lower in slow acetylators compared with rapid acetylators. In addition, there was a significant relationship (rs = 0.510 to 0.718, P < 0.001) between plasma and urinary acetylation ratios. However, the distribution of the urinary acetylation ratio was not bimodal. 5 The urinary acetylation ratio after an oral dose of DDS is not a discriminative index for determining acetylation phenotype.
Introduction
As discussed at recent symposia, there is an of particular clinical relevance (Clark, 1985;  increasing multidisciplinary interest in pharmaco- Weber & Hein, 1985; Evans, 1986) . genetics, especially in relation to the acetylation Acetylation polymorphism refers to a genetipolymorphism (Weber, 1984; Weber et al., 1983) cally determined difference in the N-acetylation and polymorphic drug oxidation (Dengler et al., capacity of a variety of clinically useful drugs 1984). Relationships between variations in the such as isoniazid, procainamide, hydralazine, metabolism of drugs associated with such poly-dapsone, sulphamethazine, and sulphasalazine morphisms and their toxic effects and the sus-as well as some putative carcinogenic arylamines ceptibility of different phenotypes to disease are (3-naphthylamine, benzidine, 4-aminobiphenyl and 2-aminofluorene) (Lunde et al., 1977; Drayer & Reidenberg, 1977; Clark, 1985; Weber & Hein, 1985) . Individuals may be phenotyped as either slow or rapid acetylators using a test drug such as isoniazid or sulphamethazine (Lunde et al., 1977; Clark, 1985) . From family studies it appears that slow acetylation is an autosomal homozygous recessive trait, while rapid acetylation is either a heterozygous or a homozygous dominant trait (Evans et al., 1960) . There are considerable interethnic differences in the frequency distribution of slow and rapid acetylators (Lunde et al., 1977; Clark, 1985) . For example, populations of Caucasians and Negroes appear to show an approximately equal percentage of slow and rapid acetylators. In contrast, in Japanese (Sunahara et al., 1961; Horai et al., 1982) and Eskimo populations, the number of slow acetylators is only about 10% (Lunde et al., 1977; Clark, 1985) . Thus, there are implications for rational drug treatment in different racial groups. To date the pharmacogenetics of N-acetylation pharmacogenetics in mainland Chinese has not been described.
Dapsone (DDS), 4,4'-diaminodiphenyl sulphone, has been widely used for the treatment of leprosy, chloroquine-resistant malaria and dermatitis herpetiformis (Weber & Hein, 1985) . It has also been used as a model drug for determining the acetylation phenotype (Gelber et al., 1971; Reidenberg et al., 1975; Carr et al., 1978; Philip et al., 1984) . Phenotyping with this drug has been shown to give results comparable with those using the elimination half-life of isoniazid or the urinary excretion ratio of acetylsulphamethazine to sulphamethazine (Gelber et al., 1971; Hanson etal., 1981) . The plasma acetylation ratio of monoacetyldapsone (MADDS) to DDS at 3 h after a single oral dose of 100 mg of DDS is commonly used for phenotyping (Reidenberg et al., 1975; Clark, 1985; Zuidema et al., 1986) . However, the possibility of using non-invasive urinary measurements has not been investigated systematically.
Thus, the aim of the present study was to investigate the N-acetylation polymorphism of DDS in a mainland Chinese population and to determine the utility of a urinary acetylation ratio (MADDS/DDS) as a more convenient method of phenotyping.
Methods
One hundred and eight unrelated healthy Chinese subjects residing in Changsha, Hunan, People's Republic of China, participated in the study. DDS and MADDS in plasma and urine were assayed by the h.p.l.c. method of Horai & Ishizaki (1985) . Slow acetylators were defined as subjects with plasma acetylation ratios (MADDS/DDS) less than 0.30 and rapid acetylators were those with a ratio greater than 0.35 (Reidenberg et al., 1975; Carr et al., 1978; Hanson et al., 1981) . This standard phenotyping method using plasma sample was compared with the use of urinary MADDS/DDS ratios measured in samples collected in the postdose 0-6, 0-12 and 0-24 h periods.
Results
The frequency distribution histogram of the plasma MADDS/DDS ratio is shown in Figure  1 . Fourteen (five females and nine males) of the 108 Chinese subjects had an acetylation ratio less than 0.30 and were therefore classified as slow acetylators. Ninety-one subjects were assigned as rapid acetylators and three subjects were indeterminate, having ratios of 0.321, 0.326 and 0.346. Thus, the frequency of slow acetylators was 13.0% with a confidence interval of 7.9 to 20.6% at the 95% level. Application of the Hardy Weinberg Law indicated that the frequency of the allele controlling recessive slow acetylators (q) was 0.360 and for the allele controlling dominant rapid acetylators (p) it was 0.640. (Reidenberg et al., 1975; Carr et al., 1978; Hanson et al., 1981) . between the acetylation ratio and plasma MADDS concentration (Figure 2b ), there was a highly significant (P < 0.001) difference in the mean value for plasma MADDS concentration between the two phenotypes (Table 1) . Although plasma MADDS concentrations in the slow acetylators were concentrated at the lower end of the observed concentration range, there was no discernible bimodal distribution. The mean values for plasma DDS concentration were marginally (P < 0.05) greater in the slow than in the rapid acetylators (Table 1) . However, plasma DDS concentrations did not correlate with the acetylation ratio (Figure 2a ). Because three of the 108 subjects (one each of rapid, indeterminate and slow acetylators) provided incomplete urine samples, they were excluded from the analysis of the urinary data. Urinary acetylation ratios derived from samples obtained during the three different urinary collection periods (0-6 vs 0-12, 0-6 vs 0-24, and 0-12 vs 0-24 h postdose) were highly correlated (r = 0.887 -0.949). The cumulative urinary excretion of DDS and MADDS and urinary metabolic ratios from samples collected during 0-6 and 0-24 h postdose periods are shown in Table 2 . The frequency histograms for the urinary acetylation ratios derived from urine samples obtained during the three collection periods are shown in Figure 3 . Although mean values of the urinary metabolic ratio and the cumulative urinary excretion of MADDS were significantly (P < 0.001) lower in slow acetylators (Table 2) and individual values of the acetylation ratio in the slow acetylators were at the lower end of the observed ranges (Figure 3) , clear bimodality was not apparent in the distribution of the urinary acetylation ratios (Figure 3) . Furthermore, although there were significant relationships between plasma and urinary acetylation ratios (rs = 0.510 -0.718, P < 0.001), the latter were not in complete concordance with the phenotyping derived from the plasma acetylation ratios.
Discussion
This study was confined to a sample of the population of Changsha, Hunan, approximately 920 km southwest of Shanghai. Therefore, it may not be possible to extrapolate the observed 13% frequency of slow acetylators to the rest of the rather large population of mainland China. In Chinese living outside of the mainland reported frequencies are 22.0 (Taiwan, Sunahara et al., 1963 ), 22.0 (Liverpool, Evans, 1963 , 21.5 (Singapore, Ellard & Gammon, 1977 ), 21.7 (Hong Kong, Ellard & Gammon, 1977 and 34.0% (Thailand, Kukongviriyapan et al., 1984) . Using the 95% confidence limits of these data and taking the sample sizes of these studies into account we have calculated that the last three of these frequencies are significantly (P < 0.05 to 0.01) higher than that observed in our study (Table 3) . Reasons for this may reflect variable demographic characteristics of the subjects, the test drugs used and environmental factors. Nonetheless, isoniazid, sulphamethazine or DDS have been shown to give concordant results on individual phenotyping (Gelber et al., 1971; Reidenberg etal., 1975; Hanson etal., 1981) , sex and age do not appear to have important influences on phenotyping (Evans et al., 1960) and the frequency of slow acetylators in patients with tuberculosis does not differ from that in normal healthy subjects (Evans, 1986 ). DDS has been used as an adequate test probe for determining acetylator phenotype (Reidenberg et al., 1975; Carr et al., 1978; Hanson et al., 1981; Philip et al., 1984; Clark, 1985) . The plasma ratio of MADDS to DDS at 3 h after a single oral dose of 100 mg of DDS is commonly used and is considered to be clinically acceptable (Reidenberg et al., 1975) . Clark (1985) stated that a possible disadvantage of the DDS method is that in a small number of individuals the metabolic ratio falls between 0.30 and 0.35 and that their phenotypes are therefore 'indeterminate'. Accordingly, we were unable to phenotype three out of the 108 subjects for this reason. Similarly, Carr et al. (1978) phenotype three out of their 50 subjects and Clark (1985) found two subjects in over 100 individuals whose metabolic ratio would not allow accurate phenotyping. Clark (1985) (Ishizaki et al., 1987) and others (Iyun et al., 1986) . Mass screening tests to define acetylator status in a selected population become more feasible and convenient if an adequate noninvasive procedure can be developed. Saliva samples have been shown to be unsuitable because of the extremely low concentrations of MADDS in saliva (Ahmad & Rogers, 1980; Peters et al., 1981) . However, the utility of urine samples does not appear to have been evaluated. According to Gelber et al. (1971) , urinary MADDS and acid-labile MADDS represent only a small fraction of the administered dose of DDS and they doubted the value of urine sampling for phenotyping with DDS. Our findings tend to support this view.
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